Press releases

Filter
152 found

New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010

28 Jan 2021

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

08 Jan 2021

MMV supports the launch of the new Fight the Fakes Alliance

07 Dec 2020

Largest clinical trial in Africa to treat COVID-19 cases before they become severe

20 Nov 2020

GSK and MMV present positive data on treatment of Plasmodium vivax malaria

19 Nov 2020

Endemic countries in South America meet to discuss new tools for malaria elimination

02 Nov 2020

Global call to boost access to lifesaving malaria treatment for pregnant women in Africa

15 Oct 2020

MMV launches the COVID Box to stimulate new drug research

10 Jun 2020

This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action

25 Apr 2020

Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria

24 Apr 2020

MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy

08 Mar 2020

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

03 Mar 2020
Laboratory image

Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million

27 Nov 2019

Country leaders pledge to boost malaria innovation and access to new and existing antimalarials

11 Nov 2019

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of P. vivax malaria

30 Oct 2019

Life-saving malaria project in Zambia to expand

25 Apr 2019

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

23 Apr 2019
Photo: Anna Wang/MMV

Europe-Africa partnership spearheads development of next-generation antimalarial drug

15 Apr 2019

MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

29 Jan 2019

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine

16 Jan 2019

World Malaria Report highlights importance of country-led efforts to defeat malaria in highest burden countries

19 Nov 2018

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

21 Sep 2018

Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners

28 Aug 2018

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

20 Jul 2018

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria

12 Jul 2018

WHO provides first-ever approval for rectal artesunate product for severe malaria

27 Feb 2018

GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria

28 Nov 2017

KAF156 enters phase IIb combination studies

21 Aug 2017

Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children

25 Jul 2017

Three MMV-supported antimalarials listed as essential medicines

16 Jun 2017

MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria

12 Jun 2017

MMV and Zydus join forces to develop new antimalarial

27 Sep 2016

UCT-H3D, MMV and international partners identify second potent antimalarial candidate

27 Jul 2016

MMV and Novartis expand partnership

15 Jun 2016

Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme

25 Apr 2016

MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day

25 Apr 2016

Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines

20 Apr 2016
children

MMV announces collaborative agreement with S Kant HEALTHCARE Ltd

10 Mar 2016

Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion

20 Nov 2015

MMV provides QIMR Berghofer AU$10 M for malaria drug development

08 Nov 2015

GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research

05 Nov 2015
Prof. Djimde and students at WANECAM Molecular Biology Workshop MRC Gambia

New study details safety and efficacy of re-treatment with Pyramax®

23 Oct 2015

New compound has the potential to treat malaria patients in a single dose

17 Jun 2015

GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon

05 Jun 2015

Merck Serono and MMV sign agreement to develop potential antimalarial therapy

01 Apr 2015

Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery

05 Feb 2015

Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial

20 Jan 2015

MMV announces collaborations with Cipla and Strides

27 Nov 2014

GSK and MMV announce start of Phase III programme of tafenoquine

28 Apr 2014

Potential new antimalarial drug identified at the University of Dundee

06 Feb 2014

Breakthrough Therapy designation for potential new anti-relapse medicine for malaria

20 Dec 2013

Campaign launched to help eliminate malaria deaths

23 Sep 2013

Australian first to advance malaria medicines

19 Aug 2013

Japan launches bold effort to fight neglected diseases

31 May 2013

Winners of malaria photo contest announced

22 Apr 2013

Japan’s First PPP to Spearhead Innovation in Global Health

08 Apr 2013

Open access initiative reveals drug hits for deadly neglected tropical diseases

13 Nov 2012

African antimalarial research bears first fruit

28 Aug 2012

MMV assesses risk of resistance

22 Aug 2012

Delivery of child-friendly antimalarial hits the 100 million mark

22 Feb 2012

Pages